eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
eXoZymes (NASDAQ:EXOZ), a pioneer in AI-engineered enzymes, announced its Q2 2025 financial results and operational highlights. The company secured a significant role in a $9M NSF-funded initiative, receiving a $3M share to develop cell-free biomanufacturing solutions. The quarter saw increased operating expenses of $1.20M and a net loss of $2.36M.
Notable achievements include a breakthrough in gram-scale NCT production with 96% yield and 99% purity. The company ended Q2 with $6.99M in cash, sufficient to fund operations through Q1 2026. Management will discuss these results and future outlook in today's earnings call at 5:00 PM ET.
eXoZymes (NASDAQ:EXOZ), pioniere negli enzimi progettati con intelligenza artificiale, ha comunicato i risultati finanziari e i punti salienti operativi del secondo trimestre 2025. La societ脿 ha ottenuto un ruolo importante in un'iniziativa finanziata dalla NSF da $9M, ricevendo una quota di $3M per sviluppare soluzioni di bioproduzione cell-free. Nel trimestre le spese operative sono aumentate a $1.20M e la perdita netta 猫 stata di $2.36M.
Tra i risultati pi霉 rilevanti figura una svolta nella produzione su scala grammi di NCT, con una resa del 96% e una purezza del 99%. La societ脿 ha chiuso il Q2 con $6.99M in contanti, importo ritenuto sufficiente a finanziare le operazioni fino al Q1 2026. Il management commenter脿 questi risultati e le prospettive nella call sugli utili di oggi alle 5:00 PM ET.
eXoZymes (NASDAQ:EXOZ), pionera en enzimas dise帽ados con IA, anunci贸 sus resultados financieros y principales hitos operativos del segundo trimestre de 2025. La compa帽铆a asegur贸 un papel relevante en una iniciativa financiada por la NSF por $9M, recibiendo una porci贸n de $3M para desarrollar soluciones de biomanufactura sin c茅lulas. En el trimestre los gastos operativos aumentaron a $1.20M y la p茅rdida neta fue de $2.36M.
Entre los logros destaca un avance en la producci贸n a escala de gramos de NCT con una rendimiento del 96% y pureza del 99%. La empresa cerr贸 el Q2 con $6.99M en efectivo, suficientes para financiar las operaciones hasta el Q1 2026. La direcci贸n comentar谩 estos resultados y las perspectivas en la llamada de resultados de hoy a las 5:00 PM ET.
eXoZymes (NASDAQ:EXOZ), AI搿� 靹り硠霅� 須唽 攵勳暭鞚� 靹犽弰旮办梾鞚� 2025雲� 2攵勱赴 鞛鞁れ爜 氚� 鞖挫榿 頃橃澊霛检澊韸鸽ゼ 氚滍憸頄堨姷雼堧嫟. 須岇偓電� $9M 攴滊鞚� NSF 歆�鞗� 頂勲鞝濏姼鞐愳劀 欷戩殧頃� 鞐暊鞚� 頇曤炒頄堨溂氅�, 氍挫劯韽�(cell-free) 氚旍澊鞓れ牅臁� 靻旊（靺� 臧滊皽鞚� 鞙勴暣 $3M鞚� 氚办爼氚涭晿鞀惦媹雼�. 頃措嫻 攵勱赴 鞓侅梾牍勳毄鞚� $1.20M鞙茧 歃濌皜頄堦碃, 靾滌啇鞁れ潃 $2.36M鞚挫棃鞀惦媹雼�.
欤检殧 靹标臣搿滊姅 攴鸽灗 攴滊 NCT 靸濎偘鞐愳劀 96% 靾橃湪瓿� 99% 靾滊弰毳� 雼劚頃� 鞝愳澊 鞛堨姷雼堧嫟. 須岇偓電� 2攵勱赴 毵� 順勱笀鞙茧 $6.99M毳� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2026雲� 1攵勱赴旯岇 鞖挫榿 鞛愱笀鞚� 於╇嫻頃橁赴鞐� 於╇秳頃╇媹雼�. 瓴届榿歆勳潃 鞓る姌 5:00 PM ET鞐� 鞐措Μ電� 鞁れ爜 旎嵓霟办姢旖滌棎靹� 鞚� 瓴瓣臣鞕� 頄ロ泟 鞝勲鞚� 雲检潣頃� 鞓堨爼鞛呺媹雼�.
eXoZymes (NASDAQ:EXOZ), pionnier des enzymes con莽us par IA, a publi茅 ses r茅sultats financiers et faits marquants op茅rationnels du deuxi猫me trimestre 2025. La soci茅t茅 a obtenu un r么le important dans une initiative financ茅e par la NSF de $9M, recevant une part de $3M pour d茅velopper des solutions de bioproduction sans cellules. Au cours du trimestre, les charges op茅rationnelles ont augment茅 脿 $1.20M et la perte nette s'est 茅lev茅e 脿 $2.36M.
Parmi les r茅alisations notables figure une perc茅e dans la production d'NCT 脿 l'茅chelle gramme avec un rendement de 96% et une puret茅 de 99%. La soci茅t茅 a cl么tur茅 le T2 avec $6.99M en liquidit茅s, suffisantes pour financer les op茅rations jusqu'au T1 2026. La direction commentera ces r茅sultats et les perspectives lors de la conf茅rence t茅l茅phonique de r茅sultats aujourd'hui 脿 17h00 ET.
eXoZymes (NASDAQ:EXOZ), ein Vorreiter f眉r KI-entworfene Enzyme, hat seine Finanzergebnisse und operativen Highlights f眉r das zweite Quartal 2025 ver枚ffentlicht. Das Unternehmen sicherte sich eine bedeutende Rolle in einer von der NSF gef枚rderten Initiative im Umfang von $9M und erhielt eine $3M-Zuweisung zur Entwicklung zellfreier Bioproduktionsl枚sungen. Die operativen Aufwendungen stiegen im Quartal auf $1.20M, und der Nettoverlust belief sich auf $2.36M.
Zu den bemerkenswerten Erfolgen z盲hlt ein Durchbruch bei der NCT-Produktion im Grammma脽stab mit einer Ausbeute von 96% und einer Reinheit von 99%. Das Unternehmen beendete das zweite Quartal mit $6.99M an liquiden Mitteln, ausreichend zur Finanzierung der Gesch盲ftst盲tigkeit bis zum Q1 2026. Das Management wird diese Ergebnisse und den Ausblick in der heutigen Earnings-Call um 17:00 Uhr ET 别谤枚谤迟别谤苍.
- Secured $3M share in $9M NSF-funded initiative for cell-free biomanufacturing
- Achieved breakthrough in NCT production with 96% yield and 99% purity in just 5 months
- Strong cash position of $6.99M supporting operations into Q1 2026
- Successfully launched two high-value projects: NCT in Q1 and Santalene in Q2
- Operating expenses increased by $1.20M compared to prior year
- Net loss of $2.36M for Q2, with YTD loss of $4.22M
- Pre-commercial status indicates no revenue generation yet
Insights
eXoZymes reports $2.36M quarterly loss with promising commercialization milestones and $6.99M cash runway into Q1 2026.
eXoZymes' Q2 update reveals a pre-commercial biotech making strategic investments while carefully managing its
Two significant commercial developments stand out: securing a
The
The cash position indicates approximately 3 quarters of runway at current burn rates, which is sufficient for near-term milestones but suggests additional financing may be needed in early 2026 absent significant revenue generation or strategic partnerships. This timeline gives management several quarters to demonstrate commercial traction before requiring additional capital.
eXoZymes demonstrates remarkable biomanufacturing efficiency with 96% yield NCT production and strategic positioning in high-value compounds.
The technical achievements highlighted in eXoZymes' update represent significant milestones in industrial biotechnology. Achieving gram-scale NCT production in just 5 months with
Their selection as a core partner in the NSF-funded initiative for modular cell-free biomanufacturing validates their technical approach. Cell-free systems eliminate many traditional bioprocess limitations, potentially enabling production of compounds toxic to living cells and simplifying downstream processing. The focus on developing a production module for santalene - a high-value fragrance compound currently derived from endangered sandalwood trees - represents an ideal target for their technology.
The company's strategic focus on nutraceuticals, medicines, and specialty chemicals positions them in high-margin markets where their technology's advantages in speed and precision matter most. Their emphasis on converting sustainable feedstocks addresses growing market demand for environmentally responsible production methods.
While still pre-commercial, the technical milestones suggest eXoZymes is progressing from proof-of-concept to process development phases. The next critical challenges will likely involve scale-up economics and optimization for commercial production. Their ability to maintain high yields and purity at larger scales will determine commercial viability, but their progress to date on high-value compounds represents a technically sound approach to biomanufacturing commercialization.
Management to host at 5:00PM Eastern Time, today.
LOS ANGELES, CALIFORNIA / / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended June 30, 2025.
Michael Heltzen, CEO of eXoZymes, states, "I'm delighted to see our team continue hitting important scientific and business development milestones as we're maturing our platform and company towards full commercialization. As a pre-commercial company, we remain focused on efficient execution and impactful capital allocation as we keep making progress towards the next value inflection points."
Second quarter 2025 and subsequent operational highlights:
Commercialization: Selected as core industry partner to advance modular cell-free biomanufacturing with a
$3 million share of the total award to develop a cell-free power plant - as well as developing a production module for santalene, an extremely high-value fragrance compound. Late July also produced a by going from concept to gram-scale NCT production in only 5 months, with a96% yield and over99% purity.Strategic Investment: Operating expenses rose by
$1.20 million for the quarter compared to prior year. The Net loss for the quarter was$2.36 million with a year to date loss of$4.22 million The additional spend was primarily due to expanded R&D and leadership hires to drive long-term growth. Ended Q2 2025 with$6.99 million in cash and cash equivalents, supporting operations into the end of Q1 of 2026.Extraordinary focus: Having launched projects for NCT in Q1 and Santalene in Q2, the eXoZymes team is continually demonstrating a focus on highly valuable natural products, and a rock-solid dedication towards making Next Gen Biomanufacturing a success.
Investors and interested parties can access the live webinar, at the time of the event through eXoZymes' . A recording and a transcript of the earnings call will also be made publicly available - typically within 48 hours after the live call.
Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.
About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.
Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.
While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.
Learn more on
eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.
eXoZymes contact
Lasse G枚rlitz, VP of Communications
(858) 319-7135
[email protected]
SOURCE: eXoZymes Inc.
View the original on ACCESS Newswire
FAQ
What were eXoZymes (EXOZ) Q2 2025 financial results?
How much funding did eXoZymes receive from the NSF initiative in 2025?
What major operational achievements did EXOZ report in Q2 2025?
When is eXoZymes Q2 2025 earnings call?
How long can eXoZymes fund its operations with current cash position?
